68825-29-6

Basic information

• Product Name: tert-butyl 2-(10H-phenothiazin-10-yl)acetate
• Synonyms: tert-butyl 2-(10H-phenothiazin-10-yl)acetate
• CAS NO: 68825-29-6
• Molecular Formula: C₁₆H₁₅NO₂S
• Molecular Weight: 313.41396
• Mol File: 68825-29-6.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 2-(10H-phenothiazin-10-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(10H-phenothiazin-10-yl)acetate(68825-29-6)
• EPA Substance Registry System: tert-butyl 2-(10H-phenothiazin-10-yl)acetate(68825-29-6)

Safety Data

• Hazardous Substances Data: 68825-29-6(Hazardous Substances Data)

Usage

General Description

Tert-butyl 2-(10H-phenothiazin-10-yl)acetate, also known as TBPA, is a chemical compound with a molecular structure consisting of a tert-butyl group attached to a phenothiazine ring through an acetate functional group. tert-butyl 2-(10H-phenothiazin-10-yl)acetate is commonly used in organic synthesis and pharmaceutical research as a building block for creating various phenothiazine derivatives. Phenothiazine derivatives have been studied for their potential therapeutic applications, such as antipsychotic, anti-inflammatory, and antihistaminic properties. TBPA is known for its stability and compatibility with a variety of chemical reactions, making it a versatile starting material for the synthesis of complex molecules with potential pharmaceutical benefits.

Upstream product

• 92-84-2 10H-phenothiazine 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 92-84-2 10H-phenothiazine 
• 1613229-94-9 1-(10H-phenothiazin-10-yl)acetone N-phenylsemicarbazone 
• 15375-56-1 1-(10H-phenothiazin-10-yl)propan-2-one 
• 1390635-97-8 {1-[2-(4-fluorophenyl)-2-oxoethyl]-1H-1,2,3-triazol-4-yl}methyl 10H-phenothiazin-10-ylacetate 
• 1390635-96-7 {1-[2-(4-bromophenyl)-2-oxoethyl]-1H-1,2,3-triazol-4-yl}methyl 10H-phenothiazin-10-ylacetate 
• 1390635-95-6 N-({1-[2-(4-cyanophenyl)-2-oxoethyl]-1H-1,2,3-triazol-4-yl}methyl)-2-(10H-phenothiazin-10-yl)acetamide 
• 1390635-94-5 N-({1-[2-(4-fluorophenyl)-2-oxoethyl]-1H-1,2,3-triazol-4-yl}methyl)-2-(10H-phenothiazin-10-yl)acetamide 
• 1390635-93-4 N-({1-[2-(4-bromophenyl)-2-oxoethyl]-1H-1,2,3-triazol-4-yl}methyl)-2-(10H-phenothiazin-10-yl)acetamide 
• 1390635-92-3 N-({1-[2-(4-chlorophenyl)-2-oxoethyl]-1H-1,2,3-triazol-4-yl}methyl)-2-(10H-phenothiazin-10-yl)acetamide 
• 1390635-91-2 N-({1-[2-(4-methoxyphenyl)-2-oxoethyl]-1H-1,2,3-triazol-4-yl}methyl)-2-(10H-phenothiazin-10-yl)acetamide 
• 1390635-90-1 N-({1-[2-(4-methylphenyl)-2-oxoethyl]-1H-1,2,3-triazol-4-yl}methyl)-2-(10H-phenothiazin-10-yl)acetamide 
• 1207-72-3 N-methylphenothiazine 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline or thioxanthenone (or similar) structure which function as autophagy inhibitors and/or histone deactylase inhibitors, and their use as therapeutics for the treatment of conditions characterized with aberrant autophagy activity and/or aberrant HDAC activity (e.g., cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, aging, heart disease, rheumatoid arthritis, infectious diseases, conditions and symptoms caused by a viral infection (e.g., COVID-19)).

Synthesis and antioxidant evaluation of novel phenothiazine linked substitutedbenzylideneamino-1,2,4-triazole derivatives

A series of novel 5-((10H-phenothiazin-10yl)methyl)-4-(substitutedbenzylideneamino)-4H-1,2,4-triazole-3-thiol derivatives (6a-i) have been synthesized from compound (1) through a multi-step reaction. The key intermediate (5) afforded a series of title com

Synthesis and anti-inflammatory activity of fused 1,2,4-triazolo-[3,4-b] [1,3,4]thiadiazole derivatives of phenothiazine

A new series of 10-((6-(substitutedphenyl)-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazol-3-yl)methyl)-10H-phenothiazine derivatives (7a-k) moiety was prepared using intermediate compound 5-((10H-phenothiazin-10-yl)methyl)-4-amino-4H-1,2, 4-triazole-3-thiol (5). The structures of newly synthesized compounds were confirmed on the basis of their 1H NMR, 13C NMR, LCMS mass, FT-IR and elemental analysis data results. All the compounds were screened for their significant anti-inflammatory activity of inhibition in paw oedema at 3h and 5h respectively, compared to the standard drug indomethacin. The Compounds 7k and 7d showed potent activity, while compounds 7g, 7b, 7j, 7i and 7c exhibited significant activity when compared to the standard drug, due to the presence of mild electron withdrawing groups such as difluoro, fluorine, chlorofluoro, nitro and chlorine derivatives which are attached to the benzene rings. 2013 Bentham Science Publishers.